Concepts (206)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Daphnia | 3 | 2019 | 10 | 2.29 | Why? |
| Pasteuria | 2 | 2019 | 2 | 1.60 | Why? |
| Biological Evolution | 2 | 2018 | 641 | 0.94 | Why? |
| Enzyme Inhibitors | 5 | 2019 | 1881 | 0.92 | Why? |
| Repressor Proteins | 2 | 2018 | 232 | 0.80 | Why? |
| Small Molecule Libraries | 2 | 2018 | 1060 | 0.78 | Why? |
| ATP-Binding Cassette Transporters | 2 | 2018 | 48 | 0.77 | Why? |
| Genetic Techniques | 1 | 2019 | 79 | 0.77 | Why? |
| Nucleosomes | 1 | 2018 | 48 | 0.75 | Why? |
| Drug Screening Assays, Antitumor | 2 | 2017 | 138 | 0.74 | Why? |
| Proton Therapy | 1 | 2018 | 34 | 0.73 | Why? |
| Isocitrate Dehydrogenase | 1 | 2017 | 33 | 0.72 | Why? |
| Histone-Lysine N-Methyltransferase | 1 | 2018 | 82 | 0.71 | Why? |
| Skull Base Neoplasms | 1 | 2018 | 52 | 0.70 | Why? |
| Parasites | 1 | 2017 | 39 | 0.69 | Why? |
| Organoplatinum Compounds | 1 | 2017 | 76 | 0.68 | Why? |
| Drug Evaluation, Preclinical | 4 | 2021 | 3347 | 0.66 | Why? |
| Antineoplastic Agents | 7 | 2019 | 3550 | 0.63 | Why? |
| Sex Characteristics | 3 | 2019 | 1120 | 0.62 | Why? |
| Models, Genetic | 1 | 2018 | 434 | 0.59 | Why? |
| Adaptation, Physiological | 1 | 2018 | 359 | 0.56 | Why? |
| Drug Discovery | 8 | 2021 | 3092 | 0.52 | Why? |
| High-Throughput Screening Assays | 7 | 2021 | 1783 | 0.46 | Why? |
| Adenosine | 1 | 2015 | 509 | 0.44 | Why? |
| Brain Neoplasms | 1 | 2018 | 669 | 0.43 | Why? |
| Cerebrovascular Disorders | 1 | 2018 | 1040 | 0.39 | Why? |
| Bacteria | 2 | 2018 | 1897 | 0.39 | Why? |
| Genetic Fitness | 2 | 2018 | 339 | 0.31 | Why? |
| Nuclear Proteins | 2 | 2018 | 321 | 0.30 | Why? |
| Cell Line, Tumor | 7 | 2019 | 3608 | 0.30 | Why? |
| Genomics | 1 | 2018 | 3118 | 0.30 | Why? |
| Host-Pathogen Interactions | 3 | 2019 | 11041 | 0.27 | Why? |
| Communicable Diseases | 1 | 2018 | 2148 | 0.26 | Why? |
| Drug Resistance, Neoplasm | 2 | 2018 | 447 | 0.25 | Why? |
| Drug Approval | 4 | 2021 | 1325 | 0.24 | Why? |
| MCF-7 Cells | 3 | 2019 | 199 | 0.24 | Why? |
| Genotype | 3 | 2019 | 4697 | 0.23 | Why? |
| L-Lactate Dehydrogenase | 3 | 2019 | 1995 | 0.23 | Why? |
| Enzyme Stability | 2 | 2018 | 72 | 0.22 | Why? |
| Transcription Factor AP-1 | 1 | 2021 | 75 | 0.22 | Why? |
| National Center for Advancing Translational Sciences (U.S.) | 1 | 2019 | 2 | 0.21 | Why? |
| Virulence | 2 | 2018 | 2172 | 0.21 | Why? |
| Phylogeny | 1 | 2019 | 13341 | 0.21 | Why? |
| Glypicans | 1 | 2019 | 4 | 0.20 | Why? |
| Multidrug Resistance-Associated Proteins | 2 | 2018 | 29 | 0.20 | Why? |
| Sex | 1 | 2018 | 2 | 0.20 | Why? |
| Sarcoma, Ewing | 1 | 2019 | 50 | 0.20 | Why? |
| Mating Preference, Animal | 1 | 2018 | 2 | 0.20 | Why? |
| Radiotherapy Dosage | 2 | 2018 | 428 | 0.19 | Why? |
| Ependymoma | 1 | 2018 | 5 | 0.19 | Why? |
| Jumonji Domain-Containing Histone Demethylases | 1 | 2018 | 28 | 0.19 | Why? |
| Optic Chiasm | 1 | 2018 | 6 | 0.19 | Why? |
| Phosphoglycerate Dehydrogenase | 1 | 2018 | 4 | 0.19 | Why? |
| Craniopharyngioma | 1 | 2018 | 11 | 0.19 | Why? |
| Bioreactors | 1 | 2019 | 115 | 0.19 | Why? |
| Spores, Bacterial | 1 | 2018 | 45 | 0.19 | Why? |
| Immunoconjugates | 1 | 2019 | 90 | 0.19 | Why? |
| Histone Demethylases | 1 | 2018 | 31 | 0.18 | Why? |
| National Institutes of Health (U.S.) | 1 | 2021 | 443 | 0.18 | Why? |
| Glutarates | 1 | 2017 | 7 | 0.18 | Why? |
| Thiourea | 1 | 2018 | 37 | 0.18 | Why? |
| Glycolysis | 1 | 2019 | 208 | 0.18 | Why? |
| Cochlea | 1 | 2017 | 23 | 0.18 | Why? |
| Mutation | 2 | 2021 | 12376 | 0.18 | Why? |
| Histones | 2 | 2018 | 371 | 0.18 | Why? |
| Genetics, Population | 1 | 2018 | 162 | 0.17 | Why? |
| Animals | 13 | 2021 | 78931 | 0.17 | Why? |
| Quinazolines | 1 | 2018 | 126 | 0.17 | Why? |
| Spheroids, Cellular | 1 | 2017 | 124 | 0.17 | Why? |
| Drug Resistance, Multiple | 1 | 2018 | 156 | 0.17 | Why? |
| Culture Media | 1 | 2019 | 366 | 0.16 | Why? |
| Host-Parasite Interactions | 1 | 2017 | 112 | 0.16 | Why? |
| Coinfection | 1 | 2017 | 6820 | 0.16 | Why? |
| THP-1 Cells | 1 | 2017 | 374 | 0.16 | Why? |
| Methylation | 1 | 2017 | 332 | 0.16 | Why? |
| Luciferases | 1 | 2018 | 378 | 0.16 | Why? |
| Cisplatin | 1 | 2017 | 209 | 0.16 | Why? |
| Radiotherapy, Intensity-Modulated | 1 | 2017 | 148 | 0.16 | Why? |
| Diketopiperazines | 1 | 2015 | 8 | 0.16 | Why? |
| Radiotherapy Planning, Computer-Assisted | 1 | 2017 | 172 | 0.16 | Why? |
| Organic Anion Transporters | 1 | 2015 | 40 | 0.15 | Why? |
| Disease Transmission, Infectious | 1 | 2019 | 9044 | 0.15 | Why? |
| 3T3 Cells | 1 | 2015 | 152 | 0.15 | Why? |
| Glioma | 1 | 2018 | 189 | 0.15 | Why? |
| Fluorescence | 1 | 2017 | 475 | 0.15 | Why? |
| Biological Assay | 1 | 2018 | 367 | 0.15 | Why? |
| Blood-Brain Barrier | 2 | 2018 | 531 | 0.14 | Why? |
| Antiviral Agents | 5 | 2021 | 41703 | 0.14 | Why? |
| Piperazines | 1 | 2018 | 445 | 0.14 | Why? |
| Data Mining | 1 | 2021 | 767 | 0.14 | Why? |
| Cell Culture Techniques | 1 | 2019 | 704 | 0.14 | Why? |
| Biological Transport | 1 | 2015 | 290 | 0.14 | Why? |
| Heterocyclic Compounds, 4 or More Rings | 1 | 2015 | 139 | 0.14 | Why? |
| Ischemic Attack, Transient | 1 | 2018 | 439 | 0.13 | Why? |
| Bacterial Infections | 2 | 2018 | 2229 | 0.13 | Why? |
| Peptide Hydrolases | 1 | 2021 | 1269 | 0.13 | Why? |
| Thiazoles | 1 | 2017 | 496 | 0.12 | Why? |
| Transcription Factors | 1 | 2018 | 784 | 0.12 | Why? |
| Rats, Sprague-Dawley | 1 | 2015 | 987 | 0.12 | Why? |
| Cell Differentiation | 1 | 2017 | 1338 | 0.11 | Why? |
| Rats | 2 | 2017 | 2764 | 0.11 | Why? |
| Enzyme-Linked Immunosorbent Assay | 3 | 2021 | 7868 | 0.11 | Why? |
| Cancer Survivors | 1 | 2018 | 588 | 0.11 | Why? |
| Sex Factors | 2 | 2018 | 11014 | 0.10 | Why? |
| United States Food and Drug Administration | 1 | 2017 | 1276 | 0.10 | Why? |
| Immunotherapy | 2 | 2020 | 2421 | 0.10 | Why? |
| Immunoglobulin A | 1 | 2021 | 3567 | 0.09 | Why? |
| Carcinoma, Hepatocellular | 1 | 2019 | 1222 | 0.09 | Why? |
| Microsomes, Liver | 2 | 2018 | 96 | 0.09 | Why? |
| Drug Resistance, Bacterial | 1 | 2018 | 1414 | 0.09 | Why? |
| Humans | 32 | 2021 | 930598 | 0.09 | Why? |
| Carcinoma, Squamous Cell | 1 | 2017 | 902 | 0.09 | Why? |
| Membrane Proteins | 1 | 2018 | 1733 | 0.09 | Why? |
| Carcinoma, Non-Small-Cell Lung | 1 | 2017 | 896 | 0.09 | Why? |
| Software | 1 | 2019 | 2501 | 0.08 | Why? |
| Mice | 5 | 2019 | 21357 | 0.08 | Why? |
| Structure-Activity Relationship | 3 | 2018 | 2219 | 0.08 | Why? |
| Drug Repositioning | 3 | 2021 | 5683 | 0.08 | Why? |
| Pyrazoles | 1 | 2017 | 1791 | 0.08 | Why? |
| Age Factors | 2 | 2018 | 21039 | 0.08 | Why? |
| Liver Neoplasms | 1 | 2019 | 1666 | 0.08 | Why? |
| Immunoglobulin M | 2 | 2021 | 9091 | 0.08 | Why? |
| Immunity | 1 | 2017 | 2651 | 0.07 | Why? |
| United States | 4 | 2021 | 46150 | 0.07 | Why? |
| HEK293 Cells | 2 | 2018 | 8394 | 0.07 | Why? |
| Oxygen | 1 | 2019 | 3715 | 0.07 | Why? |
| Cross Reactions | 3 | 2021 | 4374 | 0.07 | Why? |
| Protease Inhibitors | 1 | 2021 | 3630 | 0.07 | Why? |
| Monocytes | 1 | 2017 | 2978 | 0.07 | Why? |
| Evolution, Molecular | 1 | 2018 | 3691 | 0.07 | Why? |
| Neoplasms | 3 | 2018 | 17251 | 0.07 | Why? |
| Genetic Variation | 1 | 2018 | 3919 | 0.07 | Why? |
| Cell Line | 2 | 2018 | 12040 | 0.06 | Why? |
| Molecular Structure | 2 | 2018 | 1539 | 0.06 | Why? |
| Algorithms | 1 | 2019 | 7346 | 0.06 | Why? |
| Molecular Targeted Therapy | 2 | 2021 | 1579 | 0.05 | Why? |
| Female | 8 | 2021 | 380317 | 0.05 | Why? |
| Models, Biological | 1 | 2017 | 4907 | 0.05 | Why? |
| Laminin | 1 | 2019 | 23 | 0.05 | Why? |
| Drug Combinations | 2 | 2020 | 3852 | 0.05 | Why? |
| Immunoglobulin G | 2 | 2021 | 21571 | 0.05 | Why? |
| Virus Replication | 1 | 2021 | 14331 | 0.05 | Why? |
| Male | 7 | 2019 | 367725 | 0.05 | Why? |
| Lung Neoplasms | 1 | 2017 | 3228 | 0.05 | Why? |
| Mice, SCID | 1 | 2019 | 225 | 0.05 | Why? |
| Cyclin-Dependent Kinase 9 | 1 | 2018 | 5 | 0.05 | Why? |
| Follow-Up Studies | 1 | 2018 | 17020 | 0.05 | Why? |
| Cytosol | 1 | 2018 | 77 | 0.05 | Why? |
| Xenograft Model Antitumor Assays | 1 | 2019 | 274 | 0.05 | Why? |
| HT29 Cells | 1 | 2018 | 108 | 0.05 | Why? |
| Mice, Inbred CBA | 1 | 2017 | 16 | 0.05 | Why? |
| Stria Vascularis | 1 | 2017 | 10 | 0.05 | Why? |
| Spike Glycoprotein, Coronavirus | 4 | 2021 | 37182 | 0.05 | Why? |
| Proteoglycans | 1 | 2019 | 130 | 0.05 | Why? |
| Sequence Homology, Amino Acid | 1 | 2021 | 945 | 0.04 | Why? |
| Collagen | 1 | 2019 | 222 | 0.04 | Why? |
| Lysosomes | 1 | 2020 | 416 | 0.04 | Why? |
| Time Factors | 2 | 2018 | 31397 | 0.04 | Why? |
| Drug Synergism | 1 | 2020 | 833 | 0.04 | Why? |
| Permeability | 1 | 2017 | 238 | 0.04 | Why? |
| Solubility | 1 | 2017 | 382 | 0.04 | Why? |
| Reference Standards | 1 | 2021 | 1163 | 0.04 | Why? |
| Cell Cycle Proteins | 1 | 2018 | 297 | 0.04 | Why? |
| Antibodies, Viral | 4 | 2021 | 51949 | 0.04 | Why? |
| Membranes, Artificial | 1 | 2017 | 175 | 0.04 | Why? |
| Anti-Bacterial Agents | 1 | 2018 | 10083 | 0.04 | Why? |
| Infant | 1 | 2018 | 30274 | 0.04 | Why? |
| Databases, Genetic | 1 | 2021 | 1127 | 0.04 | Why? |
| Stroke | 1 | 2018 | 8839 | 0.03 | Why? |
| HeLa Cells | 1 | 2018 | 1303 | 0.03 | Why? |
| Hearing Loss | 1 | 2017 | 225 | 0.03 | Why? |
| Child, Preschool | 1 | 2018 | 36283 | 0.03 | Why? |
| Autophagy | 1 | 2021 | 960 | 0.03 | Why? |
| Antibodies, Neutralizing | 1 | 2020 | 25288 | 0.03 | Why? |
| Gene Expression Regulation, Neoplastic | 1 | 2019 | 1014 | 0.03 | Why? |
| DNA | 1 | 2018 | 778 | 0.03 | Why? |
| Geography | 1 | 2018 | 1801 | 0.03 | Why? |
| Mass Spectrometry | 1 | 2017 | 1165 | 0.03 | Why? |
| Cell Proliferation | 1 | 2019 | 1973 | 0.03 | Why? |
| Nanotechnology | 1 | 2018 | 821 | 0.03 | Why? |
| Adolescent | 2 | 2021 | 86841 | 0.03 | Why? |
| Young Adult | 2 | 2021 | 93724 | 0.03 | Why? |
| Crystallography, X-Ray | 1 | 2017 | 2689 | 0.03 | Why? |
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 3633 | 0.02 | Why? |
| Risk Factors | 1 | 2018 | 71621 | 0.02 | Why? |
| Child | 1 | 2018 | 70012 | 0.02 | Why? |
| Dose-Response Relationship, Drug | 1 | 2018 | 3776 | 0.02 | Why? |
| Protein Kinase Inhibitors | 1 | 2018 | 1585 | 0.02 | Why? |
| Drug Delivery Systems | 1 | 2015 | 1365 | 0.02 | Why? |
| Binding Sites | 1 | 2018 | 6201 | 0.02 | Why? |
| Interferons | 1 | 2018 | 2885 | 0.02 | Why? |
| Vero Cells | 1 | 2021 | 14117 | 0.02 | Why? |
| Adenosine Monophosphate | 1 | 2020 | 5652 | 0.02 | Why? |
| Alanine | 1 | 2020 | 5687 | 0.02 | Why? |
| Protein Binding | 1 | 2018 | 11430 | 0.01 | Why? |
| Signal Transduction | 1 | 2018 | 7207 | 0.01 | Why? |
| Pandemics | 4 | 2021 | 389249 | 0.01 | Why? |
| Immunity, Innate | 1 | 2018 | 6570 | 0.01 | Why? |
| Sensitivity and Specificity | 1 | 2021 | 22971 | 0.01 | Why? |
| Betacoronavirus | 2 | 2021 | 204454 | 0.01 | Why? |
| Hydroxychloroquine | 1 | 2020 | 12447 | 0.01 | Why? |
| Adult | 2 | 2021 | 244371 | 0.01 | Why? |
| Pneumonia, Viral | 1 | 2020 | 243684 | 0.01 | Why? |
| Coronavirus Infections | 1 | 2020 | 253789 | 0.01 | Why? |
| Middle Aged | 1 | 2021 | 270681 | 0.00 | Why? |
| Aged | 1 | 2017 | 215776 | 0.00 | Why? |
Hall's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(206)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(181)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_